1981 Volume 22 Issue 10 Pages 1538-1544
A new combination chemotherapy codenamed ACNP was designed for DCMP-resistant acute leukemia.
The protocol consisted of four to seven-day course of BH-AC 150mg/m2/day (DI) and prednisolone 20mg/m2/day (PO) along with ADR 25∼15mg/m2/day (IV) and NCS 1.5∼1.2mg/m2/day (IV) on the day 1, 2, 4 and 7. To achieve a very hypoplastic bone marrow (NCC 1×104/μl) on the day 7, the dose and the schedule were ajusted.
19 courses of ACNP were administered in 14 therapy-resistant patients with the age from 15 to 69 (median 44); AML 6, APL 3, AMoL 2, AMMoL 1, ALL 2.
7 cases (AML 4, APL 3) obtained complete remission. The median duration to reach CR was 25 days from the beginning of ACNP therapy. The median duration of CR and survival were 7 months and 12 months, respectively.
